Sarcopenia and Myosteatosis as Prognostic Markers in Patients with Advanced Cholangiocarcinoma Undergoing Palliative Treatment.
CCA
MMA
cholangiocellular carcinoma
myosteatosis
prognostic marker
sarcopenia
survival
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
23 Sep 2021
23 Sep 2021
Historique:
received:
03
09
2021
revised:
20
09
2021
accepted:
22
09
2021
entrez:
13
10
2021
pubmed:
14
10
2021
medline:
14
10
2021
Statut:
epublish
Résumé
Cholangiocarcinoma (CCA) represents the second most common primary liver cancer and is characterized by a very poor outcome, but reliable prognostic markers are largely missing. Sarcopenia, the progressive loss of muscle mass and strength, as well as myosteatosis have been associated with an unfavorable outcome in several clinical conditions, including cancer. Here, we evaluated the prognostic relevance of sarcopenia and myosteatosis using routine abdominal CT (computed tomography) scans in advanced stage CCA patients undergoing palliative treatment. Routine abdominal CT scans were used to assess the skeletal muscle and the psoas muscle index (L3SMI/L3PMI) at the level of the third lumbar vertebra as radiological indices for sarcopenia as well as the mean skeletal muscle attenuation (MMA) as a surrogate for myosteatosis. Results were correlated with clinical data and outcomes. Using a calculated optimal cut-off value of 71.95 mm Routine abdominal CT scans represent a unique opportunity to evaluate sarcopenia as well as myosteatosis in advanced CCA patients. We identified the L3SMI/L3PMI as well as the MMA as negative prognostic factors in CCA patients undergoing palliative therapy, arguing that the "opportunistic" evaluation of these parameters might yield important clinical information in daily routine.
Sections du résumé
BACKGROUND
BACKGROUND
Cholangiocarcinoma (CCA) represents the second most common primary liver cancer and is characterized by a very poor outcome, but reliable prognostic markers are largely missing. Sarcopenia, the progressive loss of muscle mass and strength, as well as myosteatosis have been associated with an unfavorable outcome in several clinical conditions, including cancer. Here, we evaluated the prognostic relevance of sarcopenia and myosteatosis using routine abdominal CT (computed tomography) scans in advanced stage CCA patients undergoing palliative treatment.
METHODS
METHODS
Routine abdominal CT scans were used to assess the skeletal muscle and the psoas muscle index (L3SMI/L3PMI) at the level of the third lumbar vertebra as radiological indices for sarcopenia as well as the mean skeletal muscle attenuation (MMA) as a surrogate for myosteatosis. Results were correlated with clinical data and outcomes.
RESULTS
RESULTS
Using a calculated optimal cut-off value of 71.95 mm
CONCLUSION
CONCLUSIONS
Routine abdominal CT scans represent a unique opportunity to evaluate sarcopenia as well as myosteatosis in advanced CCA patients. We identified the L3SMI/L3PMI as well as the MMA as negative prognostic factors in CCA patients undergoing palliative therapy, arguing that the "opportunistic" evaluation of these parameters might yield important clinical information in daily routine.
Identifiants
pubmed: 34640358
pii: jcm10194340
doi: 10.3390/jcm10194340
pmc: PMC8509694
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int J Clin Oncol. 2021 Feb;26(2):409-416
pubmed: 33104907
J Cachexia Sarcopenia Muscle. 2019 Aug;10(4):794-802
pubmed: 31037838
J Appl Physiol (1985). 2001 Jun;90(6):2157-65
pubmed: 11356778
J Am Med Dir Assoc. 2011 May;12(4):249-56
pubmed: 21527165
J Cachexia Sarcopenia Muscle. 2010 Dec;1(2):147-157
pubmed: 21475702
Int J Clin Oncol. 2021 Mar;26(3):523-531
pubmed: 33226523
World J Surg. 2021 Jul;45(7):2218-2226
pubmed: 33842995
ANZ J Surg. 2021 May;91(5):E292-E297
pubmed: 33682264
Lancet Oncol. 2021 May;22(5):690-701
pubmed: 33798493
Liver Int. 2019 May;39 Suppl 1:108-122
pubmed: 30843325
Lancet. 2014 Jun 21;383(9935):2168-79
pubmed: 24581682
Dig Dis. 2018;36(4):281-288
pubmed: 29807369
Magn Reson Imaging. 2012 Nov;30(9):1323-41
pubmed: 22770690
Clin Nutr. 2017 Oct;36(5):1187-1196
pubmed: 28689670
J Clin Med. 2021 Mar 25;10(7):
pubmed: 33806224
Oncol Rep. 2016 Mar;35(3):1727-31
pubmed: 26648321
PLoS One. 2012;7(12):e51862
pubmed: 23251644
Surgery. 2016 Mar;159(3):821-33
pubmed: 26603849
BMC Cancer. 2020 Oct 15;20(1):1002
pubmed: 33059606
ANZ J Surg. 2018 Sep;88(9):E654-E658
pubmed: 29388312
Acta Physiol (Oxf). 2014 Apr;210(4):768-89
pubmed: 24433272
Lancet. 2021 Jan 30;397(10272):428-444
pubmed: 33516341
World J Surg. 2015 Jun;39(6):1494-500
pubmed: 25651963
PLoS One. 2018 May 3;13(5):e0196235
pubmed: 29723245
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404
Eur J Cancer. 2016 Apr;57:58-67
pubmed: 26882087